The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr chr16
start 11819829
end 11828845
lncRNA name BCAR4
entrez id 400500
hgnc id HGNC:22170
ensg id ENSG00000262117
refseq id NR_024049
methods microarray, qPCR, RNAi etc.
regulated differential expression
function description As BCAR4 expression in cell lines did not change the sensitivity to different chemotherapeutic agents, the increased sensitivity to lapatinib is not due to a general mechanism of drug resistance. Also in our BCAR4-expressing cell models, the combination of lapatinib and antioestrogens was more potent in inhibiting cell growth than lapatinib alone; indicating that blocking the ERBB2 pathway with lapatinib re-sensitises BCAR4-expressing cells to antioestrogens. BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens.
pubmed id 22892392
year 2012
title BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
drug V
circulating X
survival V

CopyRight © University of Miami, USA; Harbin Medical University, China